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BoOBJECTIVES This study conducted a prospective, single-arm, multicenter trial to evaluate the safety and efﬁcacy of
ultrasound-facilitated, catheter-directed, low-dose ﬁbrinolysis, using the EkoSonic Endovascular System (EKOS, Bothell,
Washington).
BACKGROUND Systemic ﬁbrinolysis for acute pulmonary embolism (PE) reduces cardiovascular collapse but causes
hemorrhagic stroke at a rate exceeding 2%.
METHODS Eligible patients had a proximal PE and a right ventricular (RV)-to-left ventricular (LV) diameter
ratio $0.9 on chest computed tomography (CT). We included 150 patients with acute massive (n ¼ 31) or submassive
(n ¼ 119) PE. We used 24 mg of tissue-plasminogen activator (t-PA) administered either as 1 mg/h for 24 h with a
unilateral catheter or 1 mg/h/catheter for 12 h with bilateral catheters. The primary safety outcome was major bleeding
within 72 h of procedure initiation. The primary efﬁcacy outcome was the change in the chest CT–measured RV/LV
diameter ratio within 48 h of procedure initiation.
RESULTS Mean RV/LV diameter ratio decreased from baseline to 48 h post-procedure (1.55 vs. 1.13; mean
difference, 0.42; p < 0.0001). Mean pulmonary artery systolic pressure (51.4 mm Hg vs. 36.9 mm Hg; p < 0.0001) and
modiﬁed Miller Index score (22.5 vs. 15.8; p < 0.0001) also decreased post-procedure. One GUSTO (Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries)–deﬁned severe bleed (groin hematoma
with transient hypotension) and 16 GUSTO-deﬁned moderate bleeding events occurred in 15 patients (10%). No patient
experienced intracranial hemorrhage.
CONCLUSIONS Ultrasound-facilitated, catheter-directed, low-dose ﬁbrinolysis decreased RV dilation, reduced pul-
monary hypertension, decreased anatomic thrombus burden, and minimized intracranial hemorrhage in patients with
acute massive and submassive PE. (A Prospective, Single-arm, Multi-center Trial of EkoSonic Endovascular System and
Activase for Treatment of Acute Pulmonary Embolism (PE) [SEATTLE II]; NCT01513759) (J Am Coll Cardiol Intv
2015;8:1382–92) © 2015 by the American College of Cardiology Foundation.m the 1Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston,
ssachusetts; 2Cardiovascular Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School,
ston, Massachusetts; 3Syntactx, New York, New York; 4East Jefferson General Hospital, Metairie, Louisiana; 5Cardiovascular
AB BR E V I A T I O N S
AND ACRONYM S
CT = computed tomography
DVT = deep vein thrombosis
PE = pulmonary embolism
RV = right ventricular
RV/LV = right ventricular-to-
left ventricular
t-PA = tissue-plasminogen
activator
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1383T he Surgeon General estimates that 100,000to 180,000 deaths occur annually from pul-monary embolism (PE) in the United States
(1). Advanced therapies, such as systemic ﬁbrinolysis
and embolectomy, have the potential to reduce right
ventricular (RV) pressure overload in massive (2)
and submassive PE (3,4) and lower mortality by
reversing pulmonary arterial obstruction and RV
failure.
In the largest study of full-dose systemic ﬁbrino-
lysis, tenecteplase reduced the risk of death or car-
diovascular collapse by 56% in 1,006 submassive PE
patients (5). However, this beneﬁt was offset by a
nearly 5-fold increased risk of major bleeding and a
10-fold increased risk of hemorrhagic stroke. Meta-
analyses of trials of systemic ﬁbrinolysis for acute
PE have demonstrated similar ﬁndings (6,7).SEE PAGE 1393Concern over the risk of intracranial hemorrhage,
which approaches 3% to 5% outside of clinical trials
(8,9), has dampened clinician enthusiasm for full-
dose systemic ﬁbrinolysis and has sparked devel-
opment of alternative advanced therapies with
lower bleeding risk. Pharmacomechanical catheter-
directed therapy combines ﬁbrinolytic therapy with
mechanical disruption of the thrombus (10–12). The
high-frequency, low-power ultrasound component
of ultrasound-facilitated, catheter-directed, low-
dose ﬁbrinolysis is hypothesized to disaggregate
ﬁbrin ﬁbers, potentially allowing greater penetra-
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temic ﬁbrinolytic dose. This dose reduction
might improve the safety of ﬁbrinolysis for
PE. In a randomized, controlled trial of
59 patients with submassive PE in Europe,
there were no major bleeding complica-
tions with ultrasound-facilitated, catheter-
directed, low-dose ﬁbrinolysis, which rapidly
improved RV function compared with anti-
coagulation alone (14).
To expand our understanding of the
efﬁcacy and safety of ultrasound-facilitated, catheter-
directed, low-dose ﬁbrinolysis to reverse RV dysfunc-
tion in acute massive or submassive PE, we conducted
a prospective, single-arm, multicenter trial (Central
Illustration) (NCT01513759).
METHODS
STUDY DESIGN. From June 2012 to February 2013, we
screened 159 hospitalized patients with acute massive
or submassive PE and enrolled 150 in this prospective,
single-arm trial of ultrasound-facilitated, catheter-
directed, low-dose ﬁbrinolysis (Figure 1). Study pa-
tients were recruited at 22 sites across the United
States, including urban, nonurban, teaching, and
nonteaching hospitals. Institutional review board
approval was obtained at all sites, and written
informed consent was obtained for every patient. The
results of this prospective, single-arm, multicenter
trial were presented in abstract form on March 30,
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e, single-arm, multicenter trial were presented in ab-
cientiﬁc Sessions in Washington, DC.
CENTRAL ILLUSTRATION Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive
and Submassive Pulmonary Embolism
A total of 150 patients with computed tomography (CT)-conﬁrmed pulmonary embolism (PE), symptoms for 14 days or less, and a right
ventricular (RV)/left ventricular (LV) diameter ratio of at least 0.9 underwent ultrasound-facilitated, catheter-directed, low-dose ﬁbrinolysis
according to a standardized protocol. Ultrasound-facilitated, catheter-directed, low-dose ﬁbrinolysis for acute massive and submassive
pulmonary embolism (PE) improved RV function, decreased pulmonary hypertension, and minimized intracranial hemorrhage. PA ¼ pulmonary
artery; tPA ¼ tissue plasminogen.
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1384Scientiﬁc Sessions in Washington, DC. The trial was
designed and led by an Executive Committee (G.P.
and S.Z.G.) from the Study Coordinating Center. The
Executive Committee established the data analysis
plan and participated in the statistical analysis.
STUDY POPULATION. Patients were potentially
eligible to participate if they had a proximal PE (ﬁlling
defect in at least 1 main or lobar pulmonary artery),
age 18 years or older, PE symptom duration #14 days,
and RV/LV diameter ratio $0.9 on contrast-enhanced
chest computed tomography (CT). We included
patients with massive (deﬁned as syncope, systemic
arterial hypotension, cardiogenic shock, or resusci-
tated cardiac arrest) or submassive (deﬁned as a
normotensive patient with PE and evidence of RV
dysfunction) PE. Major exclusion criteria were stroke
or transient ischemic attack, head trauma, or otheractive intracranial or intraspinal disease within
12 months; major surgery within 7 days; recent active
bleeding from a major organ; hematocrit <30%;
platelets <100,000/ml; International Normalized
Ratio >3; serum creatinine >2 mg/dl; and systolic
blood pressure <80 mm Hg despite vasopressor or
inotropic support (Online Appendix). Obesity was
deﬁned as a clinical diagnosis of obesity in the med-
ical record.
ANTICOAGULATION. Anticoagulation was initiated
with full-dose intravenous unfractionated heparin
with a target activated partial thromboplastin time of
60 to 80 s. For patients who had already received
low-molecular weight heparin or fondaparinux, the
initiation of intravenous unfractionated heparin was
delayed by 12 h. After completion of the procedure, all
subjects received full anticoagulation. The drug,
FIGURE 1 Flow of Patients Through Each Stage of the Trial
One hundred ﬁfty nine patients with acute pulmonary embolism (PE) were screened for eligibility across 22 study sites. One hundred ﬁfty
patients were eligible for enrollment. One patient died before the ultrasound-facilitated, catheter-directed, low-dose ﬁbrinolytic procedure
could be completed. One hundred ﬁfteen patients had a within-window contrast-enhanced chest computed tomogram (CT) for measurement of
change in right ventricular-to-left ventricular (RV/LV) diameter ratio. Ninety eight patients had a within-window echocardiogram to estimate
48-h pulmonary artery (PA) systolic pressure. t-PA ¼ tissue-plasminogen activator.
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1385dose, frequency, and duration of anticoagulation
were selected by the attending physician.
ULTRASOUND-FACILITATED, CATHETER-DIRECTED, LOW-
DOSE FIBRINOLYSIS. The EkoSonic Endovascular
System (EKOS, Bothell, Washington) comprises
3 components: the Intelligent Drug Delivery Catheter,
a removable MicroSonic device, and a reusable Eko-
Sonic control unit. The procedure was performed by an
experienced operator from Interventional Cardiology,
Interventional Radiology, Vascular Surgery, or Car-
diothoracic Surgery. Venous access was obtained,
most often with ultrasound guidance, via the common
femoral or internal jugular vein. After catheter place-
ment but before activation of ultrasound and infusion
of ﬁbrinolytic therapy, baseline right heart pressures
were transduced through the catheters. Because the
catheters are placed in or adjacent to the PE, the
ﬁbrinolytic agent is delivered directly to the thrombus.
The ﬁxed-dose regimen of tissue-plasminogen
activator (t-PA) (Genentech, South San Francisco,
California) was 24 mg at 1 mg/h with saline coolant at
35 ml/h for both unilateral and bilateral PEs. The
ﬁbrinolytic agent is not infused under pressure, but
rather drips out of microscopic side holes. For pa-
tients with predominantly unilateral PE, a single
continuous catheter-directed pulmonary artery infu-
sion of t-PA was used for 24 h. For patients with
bilateral PE, 2 drug delivery devices were placed, anda continuous infusion of t-PA was administered in
each catheter for 12 h. No adjunctive interventional
techniques to assist thrombus removal or dissolution
were permitted. During the procedure, intravenous
unfractionated heparin was continued at intermedi-
ate intensity with a target aPTT of 40 to 60 s. After
removal of the drug delivery device(s), the access site
was manually compressed for at least 5 min. Fifteen
minutes after achieving hemostasis, full therapeutic
anticoagulation was restarted.
FOLLOW-UP. After completion of the procedure but
before catheter removal, right heart pressures were
measured. Right heart pressure measurements were
transduced once before activation of ultrasound and
infusion of ﬁbrinolytic therapy and once after
completion of the procedure. The post-procedure
invasive hemodynamic assessment was performed
at either 12 or 24 h after the initiation of ﬁbrinolysis.
In the 86% of patients with bilateral PEs who
underwent ultrasound-facilitated, catheter-directed,
low-dose ﬁbrinolysis via bilateral catheters, the post-
procedure hemodynamic assessment was performed
at 12 h after initiation of the procedure, before cath-
eter removal. For the remaining patients who had
unilateral ultrasound-facilitated, catheter-directed,
low-dose ﬁbrinolysis via a single catheter, the post-
procedure hemodynamic assessment was performed
at 24 h after initiation of the procedure, before
TABLE 1 Baseline Demographics and Clinical Characteristics
(N ¼ 150)
Patient
Age, yrs 59  16.1
Body mass index, kg/m2 35.6  9.1
Female 77 (51.3)
Ethnicity/race
Caucasian 119 (79.3)
African American 22 (14.7)
Hispanic or Latino 9 (6)
Comorbid conditions
Obesity 82 (54.7)
Concomitant use of antiplatelet medications 51 (34)
Immobility within 30 days of PE 45 (30)
Diabetes mellitus 42 (28)
Family history of venous thromboembolism 31 (20.7)
Previous DVT 30 (20)
Active tobacco use 27 (18)
Active infectious illness within 30 days of PE 20 (13.3)
Atherosclerotic cardiovascular disease 18 (12)
Previous PE 15 (10)
Values are mean  SD or n (%).
DVT ¼ deep vein thrombosis; PE ¼ pulmonary embolism.
TABLE 2 Characteristics of PE and Initial Anticoagulation
(N ¼ 150)
Any symptoms of PE 150 (100)
Duration of symptoms, days
#14 149 (99.3)
>14 1 (0.7)
PE subtype
Submassive 119 (79.3)
Massive 31 (20.7)
Pre-procedure anticoagulation*
Intravenous unfractionated heparin 76 (50.7)
Enoxaparin 54 (36)
Warfarin 16 (10.7)
Other 7 (4.7)
None 24 (16)
Values are n (%). *Patients could have received more than 1 anticoagulant.
PE ¼ pulmonary embolism.
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1386catheter removal. Multiple right heart pressure mea-
surements or “averaging” values were not allowed
for assessment of baseline and post-procedure pres-
sures. Follow-up contrast-enhanced chest CT and
transthoracic echocardiography were performed
within 48  6 h after initiation of the procedure. The
changes in the RV/LV diameter ratio and modiﬁed
Miller angiographic obstruction index score (15) were
assessed by the contrast-enhanced chest CT per-
formed at baseline and at 48 h. The maximal modiﬁed
Miller Index score is 40, corresponding with occlu-
sion of all pulmonary artery segments. Echocardiog-
raphy was performed to estimate pulmonary artery
systolic pressure at 48  6 h. All CT scans and echo-
cardiograms were analyzed at a dedicated, blinded
imaging core laboratory (Syntactx, New York, New
York).
Bleeding complications were assessed for 72 h after
the procedure. Patients were assessed clinically for
recurrent, symptomatic PE at 30 days after the pro-
cedure. Recurrent PE was deﬁned as symptomatic
and objectively conﬁrmed with contrast-enhanced
chest CT, ventilation-perfusion lung scanning, or
invasive contrast pulmonary angiography. Overall,
149 of 150 patients (99.3%) completed the required
clinical follow-up.
OUTCOMES. The primary efﬁcacy outcome was the
core laboratory–measured change in the RV/LV
diameter ratio from baseline, as assessed by contrast-
enhanced chest CT at baseline and at 48  6 h after
initiation of procedure (16). A secondary efﬁcacy
outcome was the change in pulmonary artery systolic
pressure, as assessed by baseline right heart cathe-
terization compared with measurements obtained at
the conclusion of the procedure and as estimated by
transthoracic echocardiography at 48 h. An additional
secondary outcome was the change in the modiﬁed
Miller angiographic obstruction index score, as
assessed by the baseline contrast-enhanced chest CT
and the follow-up scan performed at 48 h.
The primary safety outcome was major bleeding
within 72 h of initiation of the procedure. Bleeding
events were classiﬁed by the GUSTO (Global Utiliza-
tion of Streptokinase and Tissue Plasminogen Acti-
vator for Occluded Coronary Arteries) bleeding criteria
(Online Appendix) (17). Severe or life-threatening
bleeding was deﬁned as either intracranial hemor-
rhage or bleeding that caused hemodynamic compro-
mise and required intervention. Moderate bleeding
required blood transfusion but did not result in
hemodynamic compromise. Mild bleeding did not
meet criteria for either severe/life-threatening or
moderate bleeding. We deﬁned major bleeding as
either a GUSTO moderate or a GUSTO severe/life-threatening bleeding event. All monitoring for major
bleeding within 72 h was performed during the
hospitalization.
The secondary safety outcomes included symp-
tomatic recurrent PE up to 30 days after the initiation
of the procedure, all-cause mortality at hospital
discharge and through 30 days, and technical proce-
dural complications. Mortality was further classiﬁed
as related to cancer, myocardial infarction, PE, or
other causes. Death was attributed to PE if it was
either sudden or unsuspected or if there was evidence
to support an association with PE. All safety out-
comes, including bleeding complications, were
TABLE 3 Procedural Characteristics
Total dose of t-PA, mg* 23.7  2.9
Successful device placement† 278 (97.5)
Access sites‡
Right femoral vein 177 (63.7)
Left femoral vein 61 (21.9)
Right internal jugular vein 31 (11.2)
Other 9 (3.2)
No. of devices per patient*
0 1 (0.7)
1 20 (13.3)
2 129 (86)
Completed infusion of t-PA‡ 272 (97.8)
Values are mean  SD or n (%). *N ¼ 150 patients (1 patient died before devices
could be placed). †Devices attempted ¼ 285. ‡Devices placed ¼ 278.
t-PA ¼ tissue-plasminogen activator.
TABLE 4 Efﬁcacy Outcomes*
Outcome Baseline
At Procedure
Completion
Absolute
Difference
48 h After
Procedure
Absolute
Difference
PA systolic pressure,
mm Hg
51.4  16 37.5  11.9† 14  15 36.9  14.9‡ 14.4  15.4
RV/LV diameter ratio 1.55  0.39 – – 1.13  0.2§ 0.42  0.36
Modiﬁed Miller Index 22.5  5.7 – – 15.8  5.9k 6.6  6.3
Values are mean  SD. *All p values <0.0001. †Patients with complete right heart catheterization data ¼ 147.
‡Patients with transthoracic echocardiogram performed within both the baseline and the 48  6-h window¼ 98.
§Patients with contrast-enhanced chest computed tomography performed within both the baseline and the
48  6-h window ¼ 115. kPatients with contrast-enhanced chest computed tomography performed within both
the baseline and the 48  6-h window ¼ 116.
PA ¼ pulmonary artery; RV/LV ¼ right ventricular-to-left ventricular.
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1387adjudicated by a designated independent Study
Safety Monitor (M.R.J.).
STATISTICAL ANALYSIS. We estimated that at 48 h
after the procedure, therewould be at least a 0.27mean
decrease from baseline in the RV/LV diameter ratio,
based on a study that compared RV/LV diameter ratios
at baseline and after reperfusion in patients undergo-
ing systemic ﬁbrinolysis or surgical pulmonary embo-
lectomy for acute PE (18). A 20% decrease in the RV/LV
diameter ratio was observed in a previous systemic
ﬁbrinolysis study (19) and served as the basis for our
sample size estimate. With recruitment of 118 evalu-
able subjects in our present study, the power was
w0.89 to detect a >0.2 mean RV/LV diameter ratio
decrease, with a SD of 0.24, at a 2-sided p < 0.05 sig-
niﬁcance level by t test.
Results for continuous variables were compared
with baseline using a paired t test or Wilcoxon signed
rank test. For 2-group comparisons, a 2-sample t test
or Wilcoxon rank sum test was used for continuous
data, and the Fisher exact test was used for binary
data. All reported p values were 2-sided, and a
p value <0.05 was considered statistically signiﬁcant.
An intercept-only mixed model repeated measures
analysis was conducted with change in RV/LV diam-
eter ratio as the dependent variable and study site
(n ¼ 22) ﬁtted as a random effect to assess the vari-
ance in the change in RV/LV diameter ratio across the
study sites. All statistical analyses were performed
using SAS statistical software version 9.2 (SAS Insti-
tute, Cary, North Carolina).
ROLE OF FUNDING. The sponsor had no role in data
interpretation or writing the manuscript. G.P. and
S.Z.G. had full access to the data and had ﬁnal re-
sponsibility for the decision to submit for publication.
The sponsor of the trial was in possession of the
database.RESULTS
BASELINE DEMOGRAPHICS AND CLINICAL
CHARACTERISTICS. The mean age was 59 years
(Table 1). The mean body mass index (35.6 kg/m2) was
consistent with an obese patient population. Com-
mon risk factors for PE included obesity (55%),
immobility within 30 days of PE diagnosis (30%),
family history of venous thromboembolism (21%),
and personal history of deep vein thrombosis (DVT)
(20%) or PE (10%). Mean serum creatinine was
1.0 mg/dl.
CHARACTERISTICS OF A PE. All patients had symp-
tomatic PEs (Table 2). The duration of PE symptoms
was 14 days or less, with the exception of a single
patient who was subsequently found to have symp-
toms for more than 14 days. Submassive PE and
massive PE were observed in 79% and 21% of patients,
respectively.
PROCEDURAL CHARACTERISTICS. The mean total
dose of t-PA was 24 mg (Table 3). Of 285 devices that
were attempted to be placed, 98% were successfully
placed. Right femoral venous access was most
frequently used for device placement (64%). Ultra-
sound guidance was used in 73% of vascular access
procedures for catheter placement. Bilateral devices
were placed in 86% of patients. Bilateral catheters to
treat bilateral PE were placed through a single-access
site in the majority of patients (57%).
EFFICACY OUTCOMES. Thirty-ﬁve patients did not
have follow-up chest CT performed within the 48 
6-h window. The mean RV/LV diameter ratio de-
creased from 1.55 at baseline to 1.13 at 48  6 h after
initiation of the procedure (mean difference, 0.42;
p < 0.0001) (Table 4, Figure 2). Invasively measured
mean pulmonary artery systolic pressure decreased
from 51.4 mm Hg at baseline to 37.5 mm Hg at the
completion of the procedure (mean difference,
FIGURE 2 Efﬁcacy Outcomes
(A) Change in contrast-enhanced CT–determined mean RV/LV
diameter ratio from baseline to 48  6 h after initiation of the
ultrasound-facilitated, catheter-directed, low-dose ﬁbrinolytic
procedure. (B) Change in invasively measured mean systolic
pulmonary artery pressure from baseline to completion of the
ultrasound-facilitated, catheter-directed, low-dose ﬁbrinolysis
and to 48  6 h after the procedure as estimated by trans-
thoracic echocardiogram. (C) Change in contrast-enhanced
CT–determined mean modiﬁed Miller pulmonary angiographic
obstruction index score from baseline to 48  6 h after initiation
of the ultrasound-facilitated, catheter-directed, low-dose ﬁbri-
nolytic procedure. Abbreviations as in Figure 1.
TABLE 5 Safety Outcomes (N ¼ 150)
Length of stay, SD, days 8.8  5
In-hospital death 3 (2)
30-day mortality* 4 (2.7)
Serious and severe adverse events potentially
related to device
3 (2)
Serious and severe adverse events potentially
related to t-PA
2 (1.3)
IVC ﬁlter placed 24 (16)
Major bleeding within 30 days* 15 (10)
GUSTO moderate* 14 (9.3)
GUSTO severe* 1 (0.7)
Intracranial hemorrhage 0 (0)
Values are mean  SD or n (%). *N ¼ 149 (1 patient lost to follow-up).
GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries; IVC ¼ inferior vena cava; t-PA ¼ tissue-
plasminogen activator.
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138814 mm Hg; p < 0.0001). The decrease in mean pul-
monary artery systolic pressure was sustained from
baseline to 48  6 h, as estimated by transthoracic
echocardiography (51.4 mm Hg vs. 36.9 mm Hg; mean
difference, 14.4; p < 0.0001). Mean modiﬁed Miller
angiographic obstruction index score decreased
from 22.5 at baseline to 15.8 at 48  6 h (mean
difference, 6.6; p < 0.0001).
An analysis was conducted to determine whether
there was any difference in the change in RV/LV
diameter ratio between patients who had a follow-upCT scan performed with the 48  6-h window and
those who had a follow-up CT scan performed but it
fell outside of the 48  6-h window. There was no
difference in the change in RV/LV diameter ratio in
patients who had a follow-up CT scan performed
within the 48  6-h window and those who had a
follow-up CT scan performed but it fell outside of the
48  6-h window (mean percentage of change, 24%
vs. 29%; p ¼ 0.29). Similarly, there was no difference
in the change in pulmonary artery systolic pressure in
patients who had follow-up echocardiography per-
formed within the 48  6-h window and those
who had echocardiography performed outside of the
48  6-h window (mean percentage of change,
14.4 mm Hg vs. 17.5 mm Hg; p ¼ 0.24).
A random-effects model analysis was performed to
assess whether there was signiﬁcant variance in the
change in RV/LV diameter ratio according to study
site. There was no indication of signiﬁcant study site
variance (p ¼ 0.24), and the 2-sided p value for
comparing the mean change in RV/LV diameter ratio
with the pre-speciﬁed control value of 0.2 remained
signiﬁcant (p < 0.0001).
SAFETY OUTCOMES. Three patients died while hos-
pitalized, and 1 patient died after hospital discharge
within 30 days of the procedure (Table 5). One patient
died of massive PE before the procedure could be
completed; 1 patient changed her code status and
elected to receive hospice care after multisystem or-
gan failure developed during a prolonged admission;
1 patient died of sepsis unrelated to the procedure;
and 1 patient died of PE resulting in progressive res-
piratory failure. The patient who died before the
procedure could be completed was a 61-year-old
woman with diabetes, obesity, and recent infectious
illness who presented hemodynamically stable with
TABLE 6 Summary of GUSTO Moderate Major Bleeds
Bleeding Event Site of Bleed
Transfused Blood
Products
Hgb (g/dl) or HCT (%)
(From Baseline to Lowest) Outcome and Complications
Access site hematoma Right groin 2-U PRBCs Hgb: 13.3 to 7.5 Recovered
Access site pseudoaneurysm Right groin 2-U PRBCs HCT: 34.5 to 23.8 Recovered
Gross hematuria Genitourinary tract 4-U PRBCs Hgb: 12.6 to 7.8 Recovered
Mucosal bleeding Nasal and oropharyngeal 4-U PRBCs Hgb: 10.7 to 7.5 Recovered
Hematoma Left arm 6-U PRBCs Hgb: 13.6 to 8.1 Recovered
Hemoptysis Pulmonary 3-U PRBCs Hgb: 16.5 to 8.9 Patient was intubated and ventilated;
bronchoscopies were performed;
recovered
Anemia Unclear 4-U PRBCs HCT: 38.8 to 23.2 Recovered
Hematoma Scrotal surgery site (penile implant) 4-U PRBCs Hgb: 14.6 to 7.5 Recovered
Hematoma Abdominal surgery site (hysterectomy) 4-U PRBCs HCT: 32.1 to 23.9 Recovered
Anemia Unclear 1-U PRBCs Hgb: 11.3 to 9.8 Recovered
Access site hematoma Right groin 2-U PRBCs HCT: 37.5 to 25.2 Recovered
Hematoma Chest wall 2-U PRBCs HCT: 43.8 to 29.7 Recovered after prolonged hospitalization
Hematoma Retroperitoneal 2-U PRBCs HCT: 43.8 to 29.7 Recovered after prolonged hospitalization
Hematoma Chest wall 9-U PRBCs HCT: 42.9 to 23.4 Recovered after prolonged hospitalization
Hemoptysis Pulmonary 2-U PRBCs HCT: 33.8 to 26.3 Died of pulmonary embolism
Anemia Unclear 2-U PRBCs Hgb: 11.7 to 8.2 Recovered
GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; HCT ¼ hematocrit; Hgb ¼ hemoglobin; PRBC ¼ packed red blood cell.
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1389acute bilateral PEs to a local medical center and was
started on heparin. Her initial RV/LV diameter ratio
was 1.68, and her modiﬁed Miller Index score was
30. The following day, she was transferred to another
medical center and enrolled in the SEATTLE II
study. While the left infusion catheter was being
placed, respiratory failure developed and the patient
was intubated. She subsequently became bradycar-
dic, experienced cardiac arrest, and could not be
resuscitated.
Few serious adverse events were adjudicated to
either the device (2%) or t-PA (1.3%). No patient
experienced intracranial hemorrhage. There were 17
major bleeding events within 30 days of the proce-
dure observed in 15 patients (10%) (Table 5). All but 1
took place within 72 h of the procedure. One of these
major bleeding events was a GUSTO severe/life-
threatening hemorrhage (a right groin vascular ac-
cess site hematoma with transient hypotension
requiring vasopressor support). The remainder (94%)
were GUSTO moderate bleeds, 3 of which were related
to vascular access (Table 6). Immobility within
30 days of PE diagnosis (57.1% vs. 27.8%, p ¼ 0.03),
recent trauma (21.4% vs. 3.7%, p ¼ 0.03), and multiple
vascular access attempts (25.9% vs. 4.0%, p < 0.001)
were more frequent in patients with major bleeding
compared with those who did not have major
bleeding.
There was no signiﬁcant difference in the propor-
tion of major bleeding within 72 h of the procedure
across the 22 study sites (p ¼ 0.91).MASSIVE VERSUS SUBMASSIVE PE. The decrease in
mean RV/LV diameter ratio from baseline to 48  6 h
was similar in massive and submassive PE patients
(0.51 vs. 0.43, p ¼ 0.31). Likewise, the decrease
in mean pulmonary artery systolic pressure from
baseline to procedure completion (12.6 vs. 14.3,
p ¼ 0.61) and from baseline to 48  6 h (14.2 vs.
15.0, p ¼ 0.81) was also similar in massive and
submassive PE patients. Massive PE patients were
more likely to experience major bleeding than sub-
massive PE patients (23% vs. 7%, p ¼ 0.02).
DISCUSSION
In our study, ultrasound-facilitated, catheter-
directed, low-dose ﬁbrinolysis resulted in no epi-
sodes of intracranial hemorrhage. We observed a 25%
decrease in CT-measured RV/LV diameter ratio over
48 h, a 30% decrease in pulmonary arterial systolic
pressure by the end of the procedure, and a 30%
decrease in pulmonary artery angiographic obstruc-
tion over 48 h.
Systemic full-dose ﬁbrinolysis has been the most
extensively studied advanced therapy for patients
with acute massive and submassive PE. However, its
use even in the highest risk patients has decreased
over the past 2 decades (20), presumably due to the
high rate of intracranial hemorrhage. Clinical practice
guidelines recommend against the use of full-dose
systemic ﬁbrinolytic therapy for acute submassive
PE in all but the lowest bleeding risk patients (21–23).
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1390The desire to reduce RV pressure overload and to
minimize the risk of adverse outcomes, such as
intracranial hemorrhage, spurred exploration of
alternative lower-dose ﬁbrinolytic strategies, in-
cluding half-dose systemic ﬁbrinolysis (24,25) and
catheter-based pharmacomechanical therapy (26). In
the European ULTIMA (Ultrasound Accelerated
Thrombolysis of Pulmonary Embolism) trial of 59
patients with submassive PE, ultrasound-facilitated,
catheter-directed, low-dose ﬁbrinolysis plus anti-
coagulation improved RV function from baseline to
24 h to a greater extent than anticoagulation alone
without causing major bleeding (14). Although both
trials used the same equipment, the ULTIMA study
used a slightly lower dose of t-PA (20 mg) than the
current study (24 mg). The ULTIMA study evaluated
the procedure in 30 patients with submassive PE,
whereas the current study included 150 patients with
submassive or massive PE. The difference in the
deﬁnitions of major bleeding between the 2 trials may
partly explain the variation in major bleeding with
ultrasound-facilitated, catheter-directed, low-dose
ﬁbrinolysis (0% in the ULTIMA study vs. 10% in the
current study). In contrast to the ULTIMA study, the
current study also included massive PE patients
who were more likely to experience major bleeding
than those with submassive PE. Our study expands
the experience of ultrasound-facilitated, catheter-
directed, low-dose ﬁbrinolysis in patients with
massive and submassive PE and demonstrates the
potential of this technique. On May 21, 2014, based on
the data from our trial and previous studies, the U.S.
Food and Drug Administration approved the Eko-
Sonic Endovascular System for treatment of PE (27).
Increased RV/LV diameter ratio is a reproducible
and well-validated tool for identifying PE patients at
risk of adverse outcomes, in particular, increased
30-day mortality (28). Although a decrease in RV/LV
diameter ratio is an important surrogate marker
for the efﬁcacy of ultrasound-facilitated, catheter-
directed, low-dose ﬁbrinolysis, the need for trials
with clinical endpoints remains important (29). Clin-
ical outcomes such as hemodynamic collapse, quality
of life (30,31), and mortality will help guide the use of
this technology.
STUDY LIMITATIONS AND STRENGTHS. The major
limitation of our study was the lack of a comparator
group. Because we did not include a comparator
group, we cannot comment on the efﬁcacy or safety
of ultrasound-facilitated, catheter-directed, low-dose
ﬁbrinolysis compared with full-dose systemic ﬁbri-
nolysis, half-dose systemic ﬁbrinolysis, or anti-
coagulation alone.Another potential comparator was catheter-
directed, low-dose ﬁbrinolysis without the ultra-
sound turned “on.” A study evaluated the impact of
ultrasound on catheter-directed, low-dose ﬁbrino-
lysis for acute DVT and did not demonstrate that ul-
trasound bolstered efﬁcacy (32). However, these
ﬁndings in patients with DVT cannot be extrapolated
to acute PE because PE thrombus is more acute, less
organized, and less ﬁbrotic than DVT.
An important statistical limitation relates to a
subset of patients who did not undergo follow-up
chest CT for assessment of RV/LV diameter ratio or
echocardiography for estimation of pulmonary artery
systolic pressure within the pre-speciﬁed 48  6-h
window. Missing data could have biased the results
in favor of a greater treatment beneﬁt by removing
patients with a complicated post-procedure clinical
course and limited improvement in our study out-
comes. Alternatively, they or their physicians may
have canceled follow-up imaging because they had
excellent clinical improvement. We conducted an
analysis to explore the possibility of important dif-
ferences between the patients with and without
missing follow-up imaging data. We observed no
difference in baseline demographic, clinical charac-
teristics, comorbid conditions, PE duration or sub-
type, anticoagulation, procedural characteristics,
length of stay, or in-hospital mortality. Furthermore,
we observed no difference in the change in RV/LV
diameter ratio in patients who had a follow-up CT
scan performed within the 48  6-h window and
those who had a follow-up CT scan performed but it
fell outside of the 48  6-h window.
In summary, we created a precise protocol for
ultrasound-facilitated, catheter-directed, low-dose
ﬁbrinolysis with t-PA. Previously, there was no stan-
dardized approach. Our simpliﬁed study design
facilitated expeditious enrollment of 150 patients
within 9 months. One-half of the study population
was female. The population was also racially and
ethnically diverse, with substantial representation
of African-American and Hispanic/Latino patients.
We emphasized safety by using a deﬁnition of
major bleeding (combining GUSTO severe/life-
threatening and GUSTO moderate bleeds) that
would capture a greater number of clinically relevant
bleeding events.
FUTURE AREAS OF INVESTIGATION. Future con-
siderations include determining which patients
among those with hemodynamically stable PE are
optimal candidates for ultrasound-facilitated, cath-
eter-directed, low-dose ﬁbrinolysis. Clinical studies
with comparator groups of anticoagulation alone,
PERSPECTIVES
WHAT IS KNOWN? Ultrasound-facilitated, catheter-directed,
low-dose ﬁbrinolysis for acute massive and submassive PE
improved RV function, decreased pulmonary artery angiographic
obstruction, and reduced pulmonary hypertension.
WHAT IS NEW? The discussion of advanced therapies for pa-
tients with massive or submassive PE should include the option
of ultrasound-facilitated, catheter-directed, low-dose ﬁbrino-
lysis at medical centers with experience in the appropriate
patient selection, performance of the procedure, and post-
procedure care.
WHAT IS NEXT? Although ultrasound-facilitated, catheter-
directed, low-dose ﬁbrinolysis appeared to improve short-term,
surrogate outcomes, subsequent studies focused on clinical and
longer term outcomes will provide a better understanding of the
optimal use of this therapy for acute PE. Subsequent studies with
comparator groups of anticoagulation alone, systemic ﬁbrino-
lysis, or other catheter-based techniques will be critical in
deﬁning how ultrasound-facilitated, catheter-directed, low-dose
ﬁbrinolysis should be applied to patients with acute PE.
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1391systemic ﬁbrinolysis, or other catheter-based tech-
niques will be critical in deﬁning how ultrasound-
facilitated, catheter-directed, low-dose ﬁbrinolysis
should be used in patients with acute PE. Strategies to
reduce major bleeding related to the procedure
should also be evaluated. Health economics and
outcomes research will be critical for determining
appropriate use of this technology.
CONCLUSIONS
Ultrasound-facilitated, catheter-directed, low-dose
ﬁbrinolysis improved RV function in acute PE,
decreased pulmonary artery angiographic obstruc-
tion, reduced pulmonary artery systolic pressure,
and did not result in intracranial hemorrhage.
Ultrasound-facilitated, catheter-directed, low-dose
ﬁbrinolysis has the potential to improve outcomes
and change treatment algorithms in higher risk PE
patients.
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